Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy.
Pelzer, U Blanc, J Melisi, D Cubillo, A Von Hoff, D Wang-Gillam, A Chen, L Siveke, J Wan, Y Solem, C
Pelzer, U
Blanc, J
Melisi, D
Cubillo, A
Von Hoff, D
Wang-Gillam, A
Chen, L
Siveke, J
Wan, Y
Solem, C
Citations
Altmetric:
Abstract
Authors
Pelzer, U
Blanc, J
Melisi, D
Cubillo, A
Von Hoff, D
Wang-Gillam, A
Chen, L
Siveke, J
Wan, Y
Solem, C
Botteman, M
Yang, Y
de Jong, F
Hubner, Richard A
Blanc, J
Melisi, D
Cubillo, A
Von Hoff, D
Wang-Gillam, A
Chen, L
Siveke, J
Wan, Y
Solem, C
Botteman, M
Yang, Y
de Jong, F
Hubner, Richard A
Affiliation
Charite-Universitatsmedizin, Berlin, Germany
Description
Date
2016
Publisher
Collections
Keywords
Type
Meetings and Proceedings
Citation
Quality-adjusted time without symptoms or toxicity (Q-TWIST) of nanoliposomal irinotecan (nal-IRI;MM-398) plus 5-fluorouracil and leucavorin (5-FU/LV) vs 5-FU/LV alone in patients with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy. 2016, 39 260-260 Oncol Res Treat